PMID- 20735841
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 10
DP  - 2010 Aug 24
TI  - Molecular alterations in key-regulator genes among patients with T4 breast 
      carcinoma.
PG  - 458
LID - 10.1186/1471-2407-10-458 [doi]
AB  - BACKGROUND: Prognostic factors in patients who are diagnosed with T4 breast 
      carcinomas are widely awaited. We here evaluated the clinical role of some 
      molecular alterations involved in tumorigenesis in a well-characterized cohort of 
      T4 breast cancer patients with a long follow-up period. METHODS: A consecutive 
      series of 53 patients with T4 breast carcinoma was enrolled between 1992 and 2001 
      in Sardinia, and observed up for a median of 125 months. Archival 
      paraffin-embedded tissue sections were used for immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) analyses, in order to assess 
      alterations in expression levels of survivin, p53, and pERK1-2 proteins as well 
      as in amplification of CyclinD1 and h-prune genes. The Kaplan-Meier and Cox 
      regression methods were used for survival assessment and statistical analysis. 
      RESULTS: Overall, patients carrying increased expression of pERK1-2 (p = 0.027) 
      and survivin (p = 0.008) proteins as well as amplification of h-prune gene (p = 
      0.045) presented a statistically-significant poorer overall survival in 
      comparison with cases found negative for such alterations. After multivariate 
      analysis, the pathological response to primary chemotherapy and the survivin 
      overexpression in primary carcinoma represented the main parameters with a role 
      as independent prognostic factors in our series. CONCLUSIONS: Although 
      retrospective, our study identified some molecular parameters with a significant 
      impact on prediction of the response to therapy or prognosis among T4 breast 
      cancer patients. Further large prospective studies are needed in order to 
      validate the use of such markers for the management of these patients.
FAU - Massidda, Bruno
AU  - Massidda B
AD  - Department of Medical Oncology, University of Cagliari, Cagliari, Italy.
FAU - Sini, Mariacristina
AU  - Sini M
FAU - Budroni, Mario
AU  - Budroni M
FAU - Atzori, Francesco
AU  - Atzori F
FAU - Deidda, Mariacristina
AU  - Deidda M
FAU - Pusceddu, Valeria
AU  - Pusceddu V
FAU - Perra, Mariateresa
AU  - Perra M
FAU - Sirigu, Paola
AU  - Sirigu P
FAU - Cossu, Antonio
AU  - Cossu A
FAU - Palomba, Grazia
AU  - Palomba G
FAU - Ionta, Mariateresa
AU  - Ionta M
FAU - Palmieri, Giuseppe
AU  - Palmieri G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100824
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 0 (Carrier Proteins)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Survivin)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 3.1.3.2 (PRUNE1 protein, human)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/drug therapy/*genetics/metabolism
MH  - Carrier Proteins/*genetics/metabolism
MH  - Cyclin D1/*genetics/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Amplification
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Inhibitor of Apoptosis Proteins
MH  - Italy
MH  - Microtubule-Associated Proteins/*genetics/metabolism
MH  - Middle Aged
MH  - Mitogen-Activated Protein Kinase 1/*genetics/metabolism
MH  - Mitogen-Activated Protein Kinase 3/*genetics/metabolism
MH  - Neoplasm Staging
MH  - Phosphoric Monoester Hydrolases
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Survivin
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/*genetics/metabolism
PMC - PMC2936331
EDAT- 2010/08/26 06:00
MHDA- 2011/02/04 06:00
PMCR- 2010/08/24
CRDT- 2010/08/26 06:00
PHST- 2010/03/05 00:00 [received]
PHST- 2010/08/24 00:00 [accepted]
PHST- 2010/08/26 06:00 [entrez]
PHST- 2010/08/26 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
PHST- 2010/08/24 00:00 [pmc-release]
AID - 1471-2407-10-458 [pii]
AID - 10.1186/1471-2407-10-458 [doi]
PST - epublish
SO  - BMC Cancer. 2010 Aug 24;10:458. doi: 10.1186/1471-2407-10-458.